Quoin Q1 net loss $5M; FDA says single Phase 3 may suffice for QRX003

Quoin Pharmaceuticals, Ltd.

Net loss $5.0M in Q1 2026 vs $3.8M in Q1 2025; cash $14M expected to fund operations into 2027.
FDA granted Fast Track Designation for QRX003 (Netherton Syndrome); Type C meeting indicated single Phase 3 may support U.S. approval.
Phase 3 patient recruitment on track to complete by end of 2026; potential NDA filing in 2027.
Japan MHLW confirmed QRX003 qualifies for Orphan Drug and Fast Track review; Saudi FDA Breakthrough Medicine Designation application filed.
QRX009 topical rapamycin platform advancing; planned IND submission for additional indication by Q3 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Quoin Pharmaceuticals, Ltd. reported preliminary financial results for first quarter 2026.

Period: first quarter 2026
Result: preliminary results

Exact text from the filing

On May 7, 2026 Quoin Pharmaceuticals Ltd. (the “Company”) announced its first quarter 2026 financial results.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-26-057140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.